Children with relapsed or refractory nephroblastoma: Favorable long-term survival after high-dose chemotherapy and autologous stem cell transplantation

6Citations
Citations of this article
36Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Background: High-dose chemotherapy (HDC) with autologous stem-cell rescue (ASCR) is a treatment option for pediatric patients with relapsed nephroblastoma. We present long term results of 9 patients treated between 1993 and 2013 at our center. Procedure: Reinduction therapy was carried out according to GPOH and SIOP recommendations. The conditioning regimen consisted of carboplatin (1200mg/m 2), etoposide (800mg/m 2; or 40mg/kg) and melphalan (180mg/m 2). Purging of the grafts with immunomagnetic CD34 positive selection was performed in 5 patients. Results: 8 of 9 Patients (90%) are alive without evidence of disease after a median follow-up of 8.5 years. Leukocyte engraftment occurred after a median of 10 days (range 8-12). Median numbers of 667/μl CD3+, 329/μl CD4+, 369/μl CD8+T cells and 949/μl B cells were reached after 180 days. No negative impact of CD34 selection was observed. No transplantation-related death occurred. Acute toxicity comprised mucositis III°-IV° in all and veno-occlusive disease in one patient. Long term effects probably related to treatment occurred in 3/7 evaluable patients and comprised hearing impairment, reduced renal phosphate reabsorption, mild creatinine elevation and hypothyroidism (n=1, each). Conclusion: Thus, in our experience HDC with ASCR is an effective treatment of recurrent or refractory nephroblastoma with acceptable side effects. However, a randomized trial proving its efficiency with a high level of evidence is needed.

References Powered by Scopus

Prognostic factors for children with recurrent Wilms' tumor: Results from the second and third national Wilms' tumor study

171Citations
N/AReaders
Get full text

Treatment of Wilms tumor relapsing after initial treatment with vincristine, actinomycin D, and doxorubicin. A report from the national Wilms tumor study group

154Citations
N/AReaders
Get full text

Survival in nephroblastoma treated according to the trial and study SIOP-9/GPOH with respect to relapse and morbidity

117Citations
N/AReaders
Get full text

Cited by Powered by Scopus

FOXO3a inhibits nephroblastoma cell proliferation, migration and invasion, and induces apoptosis through downregulating the Wnt/β‑catenin signaling pathway

9Citations
N/AReaders
Get full text

Wilms’ tumour: A review of 15 years recent experience

6Citations
N/AReaders
Get full text

Multi-Omics Integration Reveals a Competitive Endogenous RNAs Network for the Identification of Progression Biomarkers and the Stratification of Patients Diagnosed With Nephroblastoma

3Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Illhardt, T., Ebinger, M., Schwarze, C. P., Feuchtinger, T., Furtwängler, R., Schlegel, P. G., … Lang, P. (2014). Children with relapsed or refractory nephroblastoma: Favorable long-term survival after high-dose chemotherapy and autologous stem cell transplantation. Klinische Padiatrie, 226(6–7), 351–356. https://doi.org/10.1055/s-0034-1390504

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 14

70%

Professor / Associate Prof. 3

15%

Researcher 3

15%

Readers' Discipline

Tooltip

Medicine and Dentistry 15

71%

Psychology 3

14%

Engineering 2

10%

Agricultural and Biological Sciences 1

5%

Save time finding and organizing research with Mendeley

Sign up for free